AstraZeneca plc (LON:AZN) has been given a consensus recommendation of “Hold” by the twenty-one ratings firms that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is GBX 4,860.33 ($64.11).
Several research analysts have recently weighed in on AZN shares. Morgan Stanley reaffirmed an “overweight” rating and issued a GBX 5,600 ($73.87) price target on shares of AstraZeneca plc in a report on Friday, June 23rd. Deutsche Bank AG reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a report on Thursday, May 4th. Barclays PLC reaffirmed an “overweight” rating and issued a GBX 6,000 ($79.15) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Liberum Capital reaffirmed a “buy” rating and issued a GBX 5,500 ($72.55) price target on shares of AstraZeneca plc in a report on Wednesday, June 14th.
In other news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($57.64) per share, for a total transaction of £1,704.30 ($2,248.12).
COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (LON:AZN) Given Average Rating of “Hold” by Analysts” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/08/03/brokerages-set-astrazeneca-plc-lonazn-pt-at-5249-18-updated.html.
Shares of AstraZeneca plc (LON AZN) traded up 1.38% during trading on Friday, hitting GBX 4562.00. The stock had a trading volume of 2,013,875 shares. The company’s market cap is GBX 57.74 billion. The firm’s 50 day moving average is GBX 5,101.58 and its 200 day moving average is GBX 4,861.19. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00.
The company also recently announced a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be issued a dividend of GBX 68.90 ($0.91) per share. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.35%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.
